Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Ozempic and Food and Drug Administration
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too complex for those manufacturers to produce safely.
Ozempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight loss and diabetes medications.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk contends that semaglutide, the active ingredient in Ozempic and Wegovy, is too complex for those manufacturers to make safely.
Roche seeks to block Novo Nordisk's Catalent deal over weight-loss drug competition
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug manufacturer Catalent, opens new tab by Novo Nordisk's controlling shareholder, as it could hit competition in the booming weight-loss drug industry.
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatment Ozempic,
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.
The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug
Novo Nordisk has asked the FDA to block production of compounded copies of Ozempic, arguing that it’s too difficult to do safely. It’s the latest escalation in a brewing war between pharmaceutical companies and compounders.
Novo asks FDA to bar compounders from making Ozempic copies
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable Difficulties for Compounding Lists."
FiercePharma
19h
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
The war is on between compounding pharmacies making knockoff versions of popular
weight
loss
drugs
and pharma giants ...
12h
Nvidia Launches Danish Sovereign AI Supercomputer That Novo Nordisk Will Use
Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by ...
NBC New York
1d
Healthy Returns: Weight loss, diabetes drugs may reduce alcohol and opioid use
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care
news
...
15h
Women turn to weight loss drugs in menopause: What to know about the benefits and risks
Losing weight in menopause can help with the severity of other menopause symptoms like hot flashes and night sweats, ...
19h
US Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
KSL
17h
Medicaid programs say cost a key factor for weight-loss drug coverage, survey finds
Most U.S. states do not currently cover highly sought-after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback